Last10K.com

Usana Health Sciences Inc (USNA) SEC Filing 10-Q Quarterly Report for the period ending Saturday, April 3, 2021

Usana Health Sciences Inc

CIK: 896264 Ticker: USNA
Exhibit 99.1


USANA Health Sciences Reports First Quarter Results

SALT LAKE CITY--(BUSINESS WIRE)--April 27, 2021--USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal first quarter ended April 3, 2021.

Key Financial & Operating Highlights

  • First quarter net sales increased 15.5% year-over-year to $308.0 million.
  • First quarter diluted EPS increased 17.9% year-over-year to $1.45.
  • Repurchased 721,000 shares for $69.5 million during the quarter.
  • Raises 2021 net sales and diluted EPS outlook.

Q1 2021 Financial Performance

Consolidated Results

Net Sales

$308.0 million

  • +15.5% vs. prior-year quarter
  • +9.3% constant currency vs. prior-year quarter
  • +$16.6 million YOY FX impact, or +6.2%

Diluted EPS

$1.45

  • +17.9% vs. prior-year quarter
  • Diluted shares of 21.1 million, -2.1%

Active Customers

617,000

  • +7.7% vs. prior-year quarter

“We had an excellent start to the year largely due to continued strong consumer demand for our high-quality products,” said Kevin Guest, Chief Executive Officer and Chairman of the Board. “Our strong top-line performance was driven by double-digit year-over-year sales growth in each of our regions, and we expect the execution of our 2021 global growth strategy will continue to generate growth in the remainder of the year.”


The following information was filed by Usana Health Sciences Inc (USNA) on Tuesday, April 27, 2021 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Usana Health Sciences Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Usana Health Sciences Inc.

Continue

Assess how Usana Health Sciences Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Usana Health Sciences Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Rating

Learn More
Bullish Bearish Neutral
Filter by Sentiment:
All
Positive
Negative
Filter by Category:
All
Revenue
Financial
Other
Filter by Subcategory:
All
Product
Earnings
Income
Shares
Expense
Geography
Other
Inside Usana Health Sciences Inc's 10-Q Quarterly Report:

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Condensed Consolidated Balance Sheets (Current Period Unaudited)
Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)
Condensed Consolidated Statement Of Stockholders' Equity (Unaudited)
Condensed Consolidated Statements Of Cash Flows (Unaudited)
Condensed Consolidated Statements Of Comprehensive Income (Unaudited)
Note A - Organization, Consolidation, And Basis Of Presentation
Note B - Fair Value Measures
Note B - Fair Value Measures (Details Textual)
Note B - Fair Value Measures (Tables)
Note B - Fair Value Measures - Schedule Of Assets And Liabilities Measured At Fair Value (Details)
Note C - Inventories
Note C - Inventories (Tables)
Note C - Inventories - Schedule Of Inventories (Details)
Note D - Investment In Equity Securities
Note D - Investment In Equity Securities (Details Textual)
Note E - Revenue And Contract Liabilities
Note E - Revenue And Contract Liabilities (Tables)
Note E - Revenue And Contract Liabilities - Schedule Of Contract Liabilities From Contract With Customers (Details)
Note E - Revenue And Contract Liabilities - Schedule Of Other Revenue (Details)
Note F - Line Of Credit
Note F - Line Of Credit (Details Textual)
Note G - Contingencies
Note H - Derivative Financial Instruments
Note H - Derivative Financial Instruments (Details Textual)
Note I - Common Stock And Earnings Per Share
Note I - Common Stock And Earnings Per Share (Details Textual)
Note I - Common Stock And Earnings Per Share (Tables)
Note I - Common Stock And Earnings Per Share - Schedule Of Earnings Per Share (Details)
Note I - Common Stock And Earnings Per Share - Schedule Of Shares Not Included In The Computation Of Diluted Eps (Details)
Note J - Segment Information
Note J - Segment Information (Details Textual)
Note J - Segment Information (Tables)
Note J - Segment Information - Consolidated Net Sales And Long Lived Assets (Details)
Note J - Segment Information - Revenues From External Customers By Geographical Areas (Details)
Note J - Segment Information - Schedule Of Revenue Percentage By Product (Details)
Significant Accounting Policies (Policies)
Ticker: USNA
CIK: 896264
Form Type: 10-Q Quarterly Report
Accession Number: 0001437749-21-011680
Submitted to the SEC: Tue May 11 2021 3:30:58 PM EST
Accepted by the SEC: Tue May 11 2021
Period: Saturday, April 3, 2021
Industry: Medicinal Chemicals And Botanical Products

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/usna/0001437749-21-011680.htm